QINTIE 2018-01-31 08:16 IP:洛阳
三门峡康瑞药业有限公司注册地址:河南三门峡;经营范围:药用果胶、果胶铋生产与销售;需求:公司整套手续转让;与投资者合作生产,引进资金用于购置设备及厂房建设。   [更多]
悬赏:
悬赏
¥30000000.00
载入中...
盐酸溴己新啊 2023-02-26 23:47 IP:XX
求购10mg注射用胸腺五肽批文。   [更多]
悬赏:
悬赏
¥5000000.00
载入中...
wuji 2013-08-12 14:40 IP:重庆
需求内容:由透明质酸均属于多糖类物质,应用该原料交联合成的水凝胶可避免异基因蛋白组分的凝胶带来的免疫学疑虑,部分厂家透明质酸凝胶产品吸水性强,与皮肤组织相容性好,可塑性强,可以根据不同需要塑性。 技术指标: 1. 体内停留时间可达到6个月以上 2. 有较好的细胞相容性、组织相容性 3. 可用于颜面部注射 4. 颗粒度均一,并可根据需要调节生产不同颗粒度的凝胶 5. 生产成本在200元/毫升以下 6. 1年内可获SFDA批准用于临床试验(含已获SFDA批准)   [更多]
悬赏:
悬赏
¥200000.00
载入中...
xiangwen521 2015-02-02 12:33 IP:长沙
标题:重金求购卡巴克络生产工艺或者原料 英文名称: Carbazochrome 中文名称: 卡巴克络 MF: C10H12N4O3 MW: 236.23 CAS: 69-81-8 要求时间:请在2015年12月之前 交稿方式:直接点击交稿在线交稿就是了,我会每天过来看的,谢谢各位药智的战友们   [更多]
悬赏:
悬赏
¥100000.00
载入中...
06070013 2013-08-02 15:58 IP:三门峡
两个药品试行标准转正,要求100%通过,寻求代理,非诚勿扰。   [更多]
悬赏:
悬赏
¥100000.00
载入中...
qing_zyq 2018-05-22 09:35 IP:沈阳
本公司因项目需要,对外委托基因毒性杂质研究:肼基、叠氮、氯代烷烃、酰氯类、氰化物等;请有研究能力的公司与我们联系。 项目要求: 1、完成以上基因毒性杂质的方法学开发、验证资料; 2、研究机构具有与实验相匹配的设备,并经过验证; 3、受委托机构可以接受审计及研制现场核查; 4、研究资料符合数据完整性要求;   [更多]
悬赏:
悬赏
¥100000.00
载入中...
wuxian3140 2015-10-16 12:41 IP:北京
品种1:抗肿瘤类,50ml西林瓶 品种2:抗生素类,5ml西林瓶 品种3:抗生素类,10ml西林瓶 以上3个品种均为冻干粉针,我公司需要寻找冻干车间,制备3批中试样品(3批注册批),主要服务是提供中试生产场地及协助我们进行中试3批生产。希望能提供服务的公司与我联系,服务价格我预估在10万左右(每个品种10万,只是我个人预估的),实际成交价格可以面谈。   [更多]
悬赏:
悬赏
¥100000.00
载入中...
lyj19721101 2015-02-06 13:34 IP:马鞍山
排行世界的第五大的制药公司寻找合作伙伴,要求提供多种大环结构药物与合成技术,寻找有关大环领域的新药发现。希望此公司提供化学详细的3 d模型。具体请链接:https://www.innocentive.com/ar/challenge/9933642 The Seeker, a top-five big pharma company, is looking for collaboration partners with expertise in the area of macrocycle drug discovery. Specifically, three key areas are of interest: Chemistry partners with access to diverse macrocyclic structures & synthetic expertise In-silico chemistry partners with access to high-throughput 3-D models suitable for macrocycles In-vitro ADME experts with access to membrane systems, beyond PAMPA and Caco-2 This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (about 2–4 pages including contact information) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the time frame agreed upon.   [更多]
悬赏:
悬赏
¥90000.00
载入中...
lyj19721101 2015-03-13 14:16 IP:马鞍山
弥漫性大B细胞淋巴瘤(DLBCL)是一种最常见的非霍奇金淋巴瘤,诊断病例在美国约占淋巴瘤的30%。它是一种特异质性疾病。由于临床多样性和复杂性,又有新的突变在某些难治性患者身上被发现。阿斯利康需要创建一种弥漫性巨大B细胞淋巴瘤的合适的临床模型。 具体链接在:https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.   [更多]
悬赏:
悬赏
¥90000.00
载入中...
zhangyangoil 2022-03-01 14:25 IP:武汉
甲基多巴  METHYL DOPA  CAS 555-30-6求购:原料药 甲基多巴的商业化生产工艺,非专利网的文献。有实际完整生产工艺的可以详谈!甲基多巴是一种抗高血压药,为白色或类白色结晶性粉末;无臭。其主要是在中枢转化成甲基去甲肾上腺素。甲基去甲肾上腺素是一种很强的中枢α2受体激动药。用于中、重度或恶性高血压,还有镇静、降低眼压作用。   [更多]
悬赏:
悬赏
¥80000.00
载入中...
发布需求,坐等药智客上门
  • 安全可靠,先验收再正式付款
  • 性价比超高,节省一半费用
  • 80%的需求得到了圆满解决
立即发布需求

推荐任务